Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Coherus Oncology formally introduces non-proprietary name: tagmokitug--Publication shows picomolar affinity for CCR8 with no off-target binding ...

Solving the Patient Enrollment Puzzle with Data-Driven Analytics

As clinical trials race against time, especially during global health emergencies, data-driven patient enrollment has become ...
Targeted Oncology

Switching to Zanubrutinib Maintains Outcomes in Waldenström Macroglobulinemia

For patients with Waldenström macroglobulinemia (WM), transitioning from ibrutinib (Imbruvica) to zanubrutinib (Brukinsa) may offer comparable clinical outcomes, as suggested by interim data from a ...
Targeted Oncology

Key Takeaways From Long-Term Follow-Up of Early CAR T in LBCL

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
MPR

Obexelimab Significantly Reduces Flare Risk in IgG4-Related Disease

Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.
Oncology Nurse Advisor

FDA Accelerated Approval for Oncology Drugs Leads to Improved Patient Survival

In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.